Perineural Injection and Supraspinatus Tendenopathy
Nyckelord
Abstrakt
Beskrivning
Baseline Evaluation
All patients were subjected to the following:
1. Thorough History Taking
1. Personal history: collected data include: age, sex, marital status, handedness, special habits and the current occupation.
2. Complaint in the patient's own words.
3. Present History he current symptoms, mode of onset, duration, , factors that may aggravate or relieve pain Characters of pain (dull aching,sharp pain ,burning sensation ,parasthesia). Distribution of pain . Review of systems: symptoms related to rheumatic conditions in particular conditions with predilection for shoulder joint affection.
Symptoms suggestive of medical disorders e.g. diabetes mellitus or thyroid dysfunction.
4. Past History Previous significant trauma(direct or occupational) orsugery to shoulder. Previous steroid injection to the shoulder. Previous injection of any type of regenerative medicine (as prp)
2. Thorough General Examination
1. General condition.
2. Vital signs (pulse, blood pressure, respiratory rate, body temperature)
3. Examination of systems (chest,cardiovascular,abdominal,neurological) to identify medical condition that may cause shoulder pain.
3-Muscloskeletal examination
1. General muscloskeletal examination
Examination of all joints for :
I.deformity,visible swelling or muscle atrophy II.Palpation for tenderness,warmth,palpable swelling either bony enlargement or synovial effusion.
III.Abnormalities in range of motion. IV.Diffuse muscloskeletal pain. V.Abnormalities of gait.
Datum
| Senast verifierad: | 04/30/2019 |
| Först skickat: | 05/06/2019 |
| Beräknad anmälan inlämnad: | 05/06/2019 |
| Först publicerad: | 05/07/2019 |
| Senaste uppdatering skickad: | 08/12/2019 |
| Senaste uppdatering publicerad: | 08/13/2019 |
| Faktiskt startdatum för studien: | 05/31/2019 |
| Uppskattat primärt slutdatum: | 09/30/2020 |
| Beräknat slutfört datum: | 12/31/2020 |
Tillstånd eller sjukdom
Intervention / behandling
Other: perineural injection group
Other: deepprolotherapy group
Fas
Armgrupper
| Ärm | Intervention / behandling |
|---|---|
| Other: perineural injection group perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years
Buffered glucose preparation :
2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.
Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :
Suprascapular nerve.. | Other: perineural injection group Buffered glucose preparation :
2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection |
| Other: deepprolotherapy group Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection . | Other: deepprolotherapy group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine |
Urvalskriterier
| Åldrar berättigade till studier | 18 Years Till 18 Years |
| Kön som är berättigade till studier | All |
| Accepterar friska volontärer | Ja |
| Kriterier | Inclusion Criteria: Patients with supraspinatous tendinopathy Exclusion Criteria: -Shoulder joint instability omplete rotator cuff tear Adhesive capsulitis Septic arthritis Malignancy Coagulopathy Connective tissue diseases Spondyloarthropathies Previous corticosteroid injection in the last six months. Previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo |
Resultat
Primära resultatåtgärder
1. change of pain from baseline [immediately before injection,2 monthes after injection,3 monthes after injection]
2. change of range of motion from base line [immediately before injection,2 monthes after injection,3 monthes after injection]
Sekundära resultatåtgärder
1. change of function from base line [immediately before injection,2 monthes after injection,3 monthes after injection]
